new_0222_0702|AMAM|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0702|AMAM|1|Ambrx Biopharma Inc Total Current Assets (Quarterly) (USD)|Ambrx Biopharma Inc Cash and Short Term Investments (Quarterly) (USD)|Ambrx Biopharma Inc Inventories (Quarterly) (USD)|Ambrx Biopharma Inc Net PP&E (Quarterly) (USD)|Ambrx Biopharma Inc Goodwill and Intangibles (Quarterly) (USD)|Ambrx Biopharma Inc Total Liabilities (Quarterly) (USD)|Ambrx Biopharma Inc Total Current Liabilities (Quarterly) (USD)|Ambrx Biopharma Inc Total Long Term Liabilities (Quarterly) (USD)|Ambrx Biopharma Inc Total Deposits (Quarterly) (USD)|Ambrx Biopharma Inc Book Value (Quarterly) (USD)|Ambrx Biopharma Inc Retained Earnings (Quarterly) (USD)|Ambrx Biopharma Inc Treasury Stock (Quarterly) (USD)|Ambrx Biopharma Inc EV to Revenues|Ambrx Biopharma Inc EV to Earnings|Ambrx Biopharma Inc EV to Free Cash Flow|Ambrx Biopharma Inc EV to Assets (Quarterly)|Ambrx Biopharma Inc PS Ratio|Ambrx Biopharma Inc PE Ratio|Ambrx Biopharma Inc Price to Book Value|Ambrx Biopharma Inc PEG Ratio|Ambrx Biopharma Inc Debt to Equity Ratio|Ambrx Biopharma Inc Dividend Yield|Ambrx Biopharma Inc Shareholder Yield (TTM)|Ambrx Biopharma Inc Percent of Shares Outstanding Short|Ambrx Biopharma Inc Total Receivables (Quarterly) (USD)|Ambrx Biopharma Inc Total Payables (Quarterly) (USD)|Ambrx Biopharma Inc Total Capital Stock (Quarterly) (USD)|Ambrx Biopharma Inc Return on Invested Capital|Ambrx Biopharma Inc Quality Ratio Score|Ambrx Biopharma Inc Momentum Score|Ambrx Biopharma Inc Beta (1Y)|Ambrx Biopharma Inc Sustainable Growth Rate (TTM)|Ambrx Biopharma Inc Institutional Investor Ownership Percentage|Ambrx Biopharma Inc Average Diluted Shares Outstanding (Quarterly)|Ambrx Biopharma Inc Total Employees (Annual)|Ambrx Biopharma Inc EPS Diluted (Quarterly) (USD)|Ambrx Biopharma Inc SG&A Expense (Quarterly) (USD)|Ambrx Biopharma Inc Shares Outstanding|Ambrx Biopharma Inc Repurchase of Capital Stock (Quarterly) (USD)|Ambrx Biopharma Inc Ordinary Shares Number (Quarterly)|Ambrx Biopharma Inc Payout Ratio|Ambrx Biopharma Inc Quick Ratio (Quarterly)|Ambrx Biopharma Inc Normalized Diluted EPS (Quarterly) (USD)|Ambrx Biopharma Inc Stock Buybacks (Quarterly) (USD)|Ambrx Biopharma Inc Effective Tax Rate (TTM)|Ambrx Biopharma Inc Return on Equity|Ambrx Biopharma Inc Net Income (TTM) (USD)|Ambrx Biopharma Inc Revenue (TTM) (USD)|Ambrx Biopharma Inc Dividend Per Share (Quarterly) (USD)|Ambrx Biopharma Inc Revenue (Quarterly) (USD)|Ambrx Biopharma Inc Gross Profit (Quarterly) (USD)|Ambrx Biopharma Inc Pre-Tax Income (Quarterly) (USD)|Ambrx Biopharma Inc Net Income (Quarterly) (USD)|Ambrx Biopharma Inc Net Interest Income (Quarterly) (USD)|Ambrx Biopharma Inc Price (USD)|Ambrx Biopharma Inc Total Return Price (USD)|Ambrx Biopharma Inc Enterprise Value (USD)|Ambrx Biopharma Inc 30-Day Average Daily Volume|Ambrx Biopharma Inc 1 Year Price Returns (Daily)|Ambrx Biopharma Inc Short Interest|Ambrx Biopharma Inc PE Ratio (Forward)|Ambrx Biopharma Inc PE Ratio (Forward 1y)|Ambrx Biopharma Inc PS Ratio (Forward)|Ambrx Biopharma Inc PS Ratio (Forward 1y)|Ambrx Biopharma Inc Quarterly EPS Estimates (USD)|Ambrx Biopharma Inc Quarterly Revenue Estimates (USD)|Ambrx Biopharma Inc Quarterly EPS Surprise|Ambrx Biopharma Inc Quarterly Revenue Surprise|Ambrx Biopharma Inc Quarterly Actual EPS (USD)|Ambrx Biopharma Inc Quarterly Actual Revenue (USD)|Ambrx Biopharma Inc Revenue Estimates for Current Fiscal Year (USD)|Ambrx Biopharma Inc Revenue Estimates for Next Fiscal Year (USD)|Ambrx Biopharma Inc Price Target (USD)|Ambrx Biopharma Inc Consensus Recommendation|Ambrx Biopharma Inc Price Target Num Estimates|Ambrx Biopharma Inc EPS Estimates for Current Fiscal Year (USD)|Ambrx Biopharma Inc EPS Estimates for Next Fiscal Year (USD)|Ambrx Biopharma Inc Research and Development Expense (Quarterly) (USD)|Ambrx Biopharma Inc Reconciled Depreciation (Quarterly) (USD)|Ambrx Biopharma Inc Non-Operating Interest Expense (Quarterly) (USD)|Ambrx Biopharma Inc Land and Improvements (Quarterly) (USD)|Ambrx Biopharma Inc Buildings and Improvements (Quarterly) (USD)|Ambrx Biopharma Inc Other Properties (Quarterly) (USD)|Ambrx Biopharma Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0702|AMAM|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0702|AMAM|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0702|AMAM|5|181|181||181|181|181|181|181||181|181||1.44117647059||1.44117647059||1.44117647059||1.43827160494||181|1.44117647059||15.3571428571|181|181|181|||||||||||8||181|181|181|||181||181|181|||||||1.44117647059|1.44117647059|1.44117647059|1.43971631206||15.3571428571|||1.44117647059|1.44117647059|92|91.25|||||56.5|113|56.5|29.8|56.5|56.5|56.5||||||181|181||
new_0222_0702|AMAM|6|1|1||1|1|1|1|1||1|1||170||170||170||162||1|170||14|1|1|1|||||||||||2||1|1|1|||1||1|1|||||||170|170|170|141||14|||34|34|1|4|||||2|1|2|5|2|2|2||||||1|1||
new_0222_0702|AMAM|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0702|AMAM|202012|93.077|90.462||3.491|36.829|273.455|13.26|260.195||-139.434|-145.553||||||||||||||0.982|2.82||||||||||||||263.6862||6.8962|||-0.0056||-16.543|13.671|||||||||||||||||||||||||||||||||||6.986|0.526||
new_0222_0702|AMAM|202103|||||||||||||||||||||||||||||||||||70|||||||||||||||||||||||||||||||3.5203||||||||||||||||||||
new_0222_0702|AMAM|202106|173.029|167.201||2.957|37.337|20.928|17.484|3.444||192.797|-174.563||42.0288|-12.9099|-12.5642|2.4233|31.9735||3.5536||||-17.047|0.0201|0.888|3.768|0.024|-150.3589||||-150.3589||||||34.9552||244.6864||9.6139|||-0.0024|-150.3589|-40.118|12.323|||||||19.6|19.6|517.9209|99249.5667||7033||||||3.5203|||||15.0406|14.7518|39.5|1.3333|2|-0.445|-0.505||||||6.667|0.551|19.55|17.81
new_0222_0702|AMAM|202109|||||||||||||24.7257||-7.3915||22.0225||2.4476|||||0.0364|||||||||||||||||||||||||||||||13.5|13.5|304.6942|17101.2333||12719|||||-0.08|4.2615|||||13.5906|14.7518|26|1.3333|1|-0.45|-0.51||||||||12.6|9.35
new_0222_0702|AMAM|202112|||||||||||||12.0461||-3.6011||14.7306||1.6372|||||0.0078|||||||||||||||||||||||||||||||9.03|9.03|148.4445|20198.9||2714|||21.3971|21.043|-0.09|4.6876||||||||1|||||||||||4.84|4.25
new_0222_0702|AMAM|202203||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||3||||||||||||||||||||